Brian Maguire

April 12, 2021

Brussels-based journalist, producer, broadcaster, and events moderator, Brian Maguire, hosts live radio and television debates with European Commissioners, Ambassadors, Members of the European Parliament and independent experts. A EURONEWS and Irish television contributor, he also presents the EURACTIV digital technology series ‘The Presidency’ and the political interview series ‘Over A Coffee’. He specialises in European politics and business, producing short documentary films and news reports exploring Europe’s competing policy dimensions, including the digital economy, the Green Deal, human rights, and the rule of law. A graduate in Government and Law, he is currently completing a Master in Laws pecializing in Tech, Media and Telecoms, at the Centre for Commercial Law Studies (CCLS), Queen Mary University of London, in Paris.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor